Frost & Sullivan Applauds Gamma Medica for Improving the Quality and Efficiency of Breast Cancer Diagnosis with its Unique LumaGEM MBI System
MOUNTAIN VIEW, Calif., July 29, 2014 /PRNewswire/ — Based on its recent analysis of the breast imaging systems market, Frost & Sullivan recognizes Gamma Medica with the 2014 Global Frost & Sullivan Award for Product Leadership. Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system provides breast images through the digital direct conversion of photons in gamma rays into electronic charges that form the image. It equips clinicians with MBI technology to detect tumors in women with dense breast tissue and plan treatment measures as early as possible.
Gamma Medica has demonstrated its dedication to improving the standard of care for breast cancer patients by offering the advanced cadmium zinc telluride (CZT) solid state detector technology in its LumaGEM MBI system.
“While other adjunct technologies such as ultrasound and magnetic resonance imaging are available, either their inability to locate microcalcifications or their low specificity can throw up inconclusive results,” said Frost & Sullivan Research Analyst Raghuraman Madanagopal. “On the other hand, Gamma Medica’s LumaGEM MBI system can efficiently locate lesions as small as 5 millimeters in size and help identify the tumor as benign or cancerous.”
The LumaGEM MBI system has the highest negative predictive value (NPV) among adjunct technologies used for breast cancer diagnosis, making it one of the most reliable systems for this purpose. It also has a high intrinsic spatial resolution of 1.6 millimeters and provides high-quality images that enable clinicians to locate tumors, measure them, and understand their functional and metabolic activities.
While there are shortcomings with every adjunct technology that is used for breast cancer diagnosis, the LumaGEM MBI system, with a high sensitivity of 91 percent and a high specificity of 93 percent, offers customers unprecedented precision. The LumaGEM MBI system utilizes a dual-head technology that effectively locates cancers in cases that previously were either inconclusive or determined to be negative on mammography images.
As the imaging is done on the mediolateral oblique and the cranio-caudal planes, it is easily comparable to mammography images. The scanning procedure in the LumaGEM MBI system uses minimal compression and is performed with the subject in a seated position.
“The LumaGEM MBI system has a small-sized gamma camera that is located closer to the breasts,” noted Raghuraman Madanagopal. “As a result, the amount of radiation required for obtaining images is less than one-third of the amount used in most breast-specific gamma imaging modalities. Frost & Sullivan research shows that this ability provides Gamma Medica a technological advantage over its competitors.”
“Gamma Medica is committed to making MBI a more widely used tool in the battle against breast cancer,” said Jim Calandra, president and chief executive officer of Gamma Medica. “We are pleased to have been recognized by Frost & Sullivan for our efforts and are excited to drive breast cancer diagnosis technology forward with highly advanced, patient-friendly and cost-effective tools.”
Gamma Medica has made its products commercially available throughout the United States, as well as in certain parts of Europe, and hopes to expand to other regions of the world. By utilizing innovative technologies and effective growth strategies, Gamma Medica has ensured a superior competitive position for itself in the global breast imaging systems market.
Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
MELBOURNE, Australia, July 29, 2014 /PRNewswire/ — Next phase of the TPM®/Oxymorphone clinical development program has commenced TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4 2014 TPM®/Oxymorphone Phase 2 trial to be…
Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma
DARMSTADT, Germany, July 29, 2014 /PRNewswire/ —
- First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel cell carcinoma (mMCC)
- mMCC is a rare and aggressive skin cancer lacking effective treatments
- MSB0010718C is also currently being explored in a seven cohort Phase I clinical trial for the treatment of solid tumors that aims to recruit 590 patients
Merck Serono, the biopharmaceutical division of Merck, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). This multicenter, single-arm, open-label study is being conducted in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin tumor,, who have previously received one line of chemotherapy. It is expected to recruit 84 patients across Asia Pacific, Australia, Europe and North America. The primary endpoint of the study is overall response.
The PD-L1/PD-1 pathway is implicated as a major mechanism by which tumors evade elimination by the immune system. The PD-L1 molecule is expressed in many cancer types, including mMCC., MSB0010718C, which blocks the interaction of PD-L1 with its receptor PD-1, may have the potential to restore effective anti-tumor T-cell responses and thereby to inhibit tumor growth.
Immune mechanisms are implicated in the pathogenesis of MCC, with an increased risk observed in immunosuppressed individuals. MCC also is associated with the presence of the Merkel cell polyomavirus, which may have a role in tumor formation. Globally, the incidence of MCC is increasing, and outcomes for patients with this disease are poor., Therefore, new treatment approaches are required to improve the outcome of patients with this type of cancer.
“We believe that modulating the immune system by targeting PD-L1 represents a promising new approach in the treatment of this aggressive cancer, especially considering that many of the predisposing factors for mMCC seem to be related to functional disruptions of the immune system,” said Helen Sabzevari, Senior Vice President of Immuno-Oncology at Merck Serono. “Our anti-PD-L1 compound may present a potential new approach for the treatment of mMCC patients. The initiation of this Phase II study is an important milestone, as we endeavor to help those suffering from mMCC, a devastating disease with significant unmet need.”
In addition to this new study in mMCC, MSB0010718C is currently being explored in a Phase I clinical trial for the treatment of solid tumors. The study aims to recruit 590 patients and has enrolled 422 patients to date. On June 1, 2014, Merck Serono presented initial data from this dose escalation study in solid tumors at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago. This study is currently recruiting patients into expansion cohorts in seven cancer types: castrate-resistant prostate cancer, colorectal cancer, gastric/gastroesophageal cancer, melanoma, metastatic breast cancer, non-small cell lung cancer and ovarian cancer.
- Hughes MP, et al. Curr Dermatol Rep 2014;3:46-53.
- Kaae J, et al. J Natl Cancer Inst 2010;102(11):793-801.
- Lipson EJ, et al. Cancer Immunol Res 2013;1(1):54-63.
- McDermott DF and Atkins MB. Cancer Med 2013; 2(5):662-73.
- Bhatia S, et al. Curr Oncol Rep 2011;13(6):488-97.
- Feng H, et al. Science 2008;319(5866):1096-100.
- Heery CR, et al. J Clin Oncol 2014;32:5(Suppl.) Abstract No. 3064.
MSB0010718C is an investigational fully human IgG1 monoclonal antibody that binds to the PD-L1 (programmed death-ligand 1) protein, which is present at high levels in many cancer types. By competitively blocking the interaction with PD-1 receptors, it is believed that MSB0010718C thereby restores anti-tumor T-cell responses.
About Merkel cell carcinoma (MCC)
MCC is a rare and aggressive disease in which cancer cells form in the top layer of the skin, close to nerve endings. MCC, which is also known as neuroendocrine carcinoma of the skin or trabecular cancer, often starts in those areas of skin that are most often exposed to the sun, including the head and neck, arms, legs, and trunk. Risk factors for MCC include sun exposure and having a weak immune system (i.e., solid-organ transplant recipients, people with HIV/AIDS and people with other cancers, such as chronic lymphocytic leukemia, are at higher risk). Caucasian males over age 50 are at increased risk.
MCC tends to metastasize at an early stage, spreading initially to nearby lymph nodes, and then potentially to more distant areas in the body, including other lymph nodes or areas of skin, lungs, brain, bones, or other organs.
Current treatment options for MCC include surgery, radiation and chemotherapy. Treatment for metastatic or Stage IV MCC is generally palliative.
About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit http://www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges.
Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.
Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.
Advanced First Aid Research Announces N95 Partnership with SilverACE Senior Activity Centres and Lions Befrienders to Help Elderly Combat Haze
SINGAPORE, July 29, 2014 /PRNewswire/ — Singapore healthcare company, Advanced First Aid Research, an innovator in first aid and burn relief solutions, today reinforced its commitment to supporting the health, wellbeing and preparedness of Singaporeans with the announcement of a sponsorship initiative in partnership with NTUC Health Co-operative’s SilverACE Senior Activity Centres and Lions Befrienders, designed to support the Nation’s most vulnerable citizens.
Goh Boon Han (left) from Lions Befrienders with Allen Loh (right), CEO of Advanced First Aid Research with the Aluminaid N95 masks.
Ahead of the anticipated haze, Advanced First Aid Research has announced it will donate one N95 mask for each one sold through Unity Pharmacies nationwide. The donated masks will be supplied to vulnerable elderly, specifically those who are members of the SilverACE Senior Activity Centres (SACs). SACs are a government initiative to support the lower income elderly with weak family support.
Donated masks will similarly be distributed to elderly citizens by the Lions Befrienders support network which reaches over 5,000 seniors through the social and community programmes.
Advanced First Aid Research’s innovative N95 mask design features an electrostatic filter that delivers better ventilation, easier breathing and speaking due to its 99 per cent filtration efficiency against micron particles. The mask also offers longer, more lasting protection against the haze and other harmful gases in a way not catered for by standard masks.
Advanced First Aid Research CEO, Allen Loh, says: “While we sincerely hope that the projected haze does not adversely impact the health of Singaporeans, it’s important we ensure that those most in need of support are prepared well in advance, and don’t miss out during times of high demand. The mask with its high filtration efficiency is ideally suited for those most susceptible to haze conditions.
“This initiative in partnership with SilverACE Senior Activity Centres and Lions Befrienders complements the good work of other government agencies and organisations who are equally committed to protecting our nation’s health during the haze season as well as the Nation’s first aid preparedness overall.”
“As a Singaporean company, we understand the local challenges on the ground and have all experienced the limitations of the current products in the market. We are delighted to extend this partnership with SilverACE Senior Activity Centres and Lions Befrienders in a way that reinforces our overall commitment to improve the health and safety of Singaporeans,” Mr Loh added.
During the haze season, the number of patients admitted into hospital for respiratory problems increases by 20 per cent. In general, the elderly, children and people with chronic lung disease and heart disease are more sensitive to the health effects of haze.
Goh Boo Han, Executive Director, Lions Befrienders, says: “We are delighted to be a part of this initiative at a time when N95 masks are in demand due to the anticipated haze. We see this as a positive and proactive measure undertaken by a local company to help the needy and vulnerable elderly.”
Leon Luai, Head Clinical Services and Wellness for NTUC Health, who oversees the SilverACE SACs, says: “We work to empower the elderly to take charge of their health and avoid many of the common health problems they face today. For instance, we have self-help health check stations at our six SACs and we regularly conduct health checks for the seniors. We are happy to partner with Advanced First Aid Research to enable seniors from lower-income families to access quality N95 masks and to ensure that they can be protected during the haze.”
“We are pleased to be part of this meaningful initiative to do more to care for the health of our community. For every mask purchased, Unity customers can equip themselves and their families and also contribute to support needy elderly in Singapore during the haze,” said Bernard Lee, MD and Head, Pharmacy and Health food NTUC Health, who also oversees Unity pharmacies.
Unity pharmacies were among the first to bring in fresh supply of N95 masks during the peak of the haze last year, and they also brought the prices of the masks down to ensure that more working families would be able to obtain the item.
Advanced First Aid Research’s N95 masks are available now in Unity Pharmacies across Singapore in packs of 10 and 20 masks. A 10-piece pack retails for $18.80 while a 20-piece pack retails for $37.80. Advanced First Aid Research will donate a N95 mask to SilverACE Senior Activity Centres and Lions Befrienders for each one sold for the duration of the haze period.
1. Fiona Low, Asthma and Allergy cases up as haze worsens: Docs, The Straits Times. Available from https://www.healthxchange.com.sg/News/Pages/Asthma-and-allergy-cases-up-as-haze-worsens.aspx
2. Health Promotion Board, Impact of Haze on Health. Available from http://www.hpb.gov.sg/HOPPortal/health-article/HPB051226
BIRMINGHAM, Ala., July 29, 2014 /PRNewswire/ — Southern Research Institute today announced that Arthur J. Tipton, Ph.D., President and CEO of Southern Research Institute, has been named president of the Controlled Release Society (CRS) for the 2014-2015 term. The inauguration took place at the Society’s annual meeting on July 12 in Chicago with attendees from more than 40 countries.
Arthur J. Tipton, Ph.D. Named President of Controlled Release Society
The Controlled Release Society is an international, interdisciplinary, not-for-profit organization whose guiding purpose is the advancement of delivery science and technology. CRS is the home for experts dedicated to the science of delivery, including delivery scientists, engineers, clinicians, and technical professionals. The primary interest of about 70% of the CRS membership is in the pharmaceutical area (including ~18% animal health) and 30% in the non-pharmaceutical areas (called consumer and diversified products).
Dr. Tipton has worked in the pharmaceutical and biotechnology industries for more than 25 years. During that time, he has pioneered the use of controlled release technologies through his work in polymer science and engineering.
“It is an honor to be named president of the Controlled Release Society,” said Dr. Tipton. “Over the past several decades, controlled release formulations have changed the treatment paradigm for a number of serious health conditions, including cancer, pain management, cardiovascular and central nervous system disorders, and have been involved in many industrial applications such as food flavorings and long acting fertilizers. As controlled release technologies continue to mature, industry and academia are meeting the challenges of developing the next generation of faster, safer, more accessible formulations, and CRS represents the world’s leaders in advancing these novel techniques. I look forward to leading this distinguished and important group.”
Previously Dr. Tipton held senior positions at Durect Corporation, its wholly-owned subsidiary Southern BioSystems, Birmingham Polymers, and Atrix Laboratories. In 2005, he founded Brookwood Pharmaceuticals, which was subsequently acquired by SurModics and later by Evonik. At Evonik, he served as senior vice president of the Birmingham Division and also led the company’s global drug delivery program. Dr Tipton has 31 issued U.S. patents, 22 published U.S. patent applications, and numerous foreign equivalents, with more than 70 presentations and publications.
He is a fellow of AIMBE and CRS and was awarded the CRS Distinguished Service Award in 2012. He serves as an external advisor to the Biomedical Engineering Department at the University of Alabama at Birmingham, and volunteers as a mentor and judge in business plan competitions. His election as president of CRS marks the first time in the organization’s 36 year history that it has been led by two individuals of the same organization. Danny H. Lewis, Ph.D., former Head, Biosystems Division for Southern Research Institute, served as president of CRS for the 1982-1983 term.
In his role as president of the Controlled Release Society, Dr. Tipton will continue to serve on the CRS Board of Directors as well as the boards of the Birmingham Venture Club, the Economic Development Partnership of Alabama Foundation, the Biotech Association of Alabama, and as a member of the Alabama Workforce Council spearheaded by Governor Robert Bentley.
Dr. Tipton earned a Ph.D. in Polymer Science and Engineering from the University of Massachusetts in Amherst, and a B.S. in Chemistry from Spring Hill College.
About Southern Research Institute
Southern Research Institute is a not-for-profit 501(c)(3) scientific research organization founded in 1941 that conducts preclinical drug discovery and development, advanced engineering research in materials, systems development, and environment and energy research. Approximately 500 scientific and engineering team members support clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental, and energy industries. Southern Research is headquartered in Birmingham, AL, with additional laboratories and offices in Wilsonville and Huntsville, AL, Frederick, MD, Durham, NC, Houston, TX, and Cartersville, GA. For more information visit: http://www.southernresearch.org.
Contact: Jonathan M. Nugent
The International Society of Aesthetic Plastic Surgery Releases Statistics on Cosmetic Procedures Worldwide
NEW YORK, July 28, 2014 /PRNewswire/ — More than 23 million cosmetic surgical and nonsurgical procedures were performed worldwide in 2013, according to statistics released today by the International Society of Aesthetic Plastic Surgery (ISAPS), the leading international society for aesthetic plastic surgery with more than 2,700 board-certified aesthetic plastic surgeon members in 95 countries. For the first time, Brazil edges out the United States in terms of the number of surgical procedures performed, and Botulinum Toxin takes the number one position for number of overall cosmetic procedures performed.
For the full report of ISAPS statistics along with a press release and a Quick Facts reference guide, click here.
As ISAPS prepares to host its 22nd Biennial Congress in Rio de Janeiro, Brazil in September, this new data will spark debate among the surgeons gathering from 75 countries to share new techniques and discuss cutting-edge information about this expanding field.
“Since our last survey was conducted, we have improved our strategy for gathering data based on statistically sound samples,” noted Carlos Uebel, MD, ISAPS president. “This has been an effort on the part of our society to further enhance our survey methodology and make it more comprehensive,” he continued.
The countries that performed the most cosmetic surgical and nonsurgical procedures in 2013 include:
- United States – 3,996,631 — (17%)
- Brazil– 2,141,257 — (9.1%)
- Mexico – 884,353 — (3.8%)
- Germany – 654,115 — (2.8%)
- Spain – 447,177 — (1.9%)
The leading cosmetic surgical procedures performed in 2013 were:
- Breast Augmentation — (1,773,584)
- Liposuction (1,614,031)
- Blepharoplasty (1,379,263)
- Lipostructure including lipofilling and stem-enhanced lipofilling (1,053,890)
- Rhinoplasty (954,423)
The leading nonsurgical procedures performed were:
- Botulinum Toxin (5,145,189)
- Fillers and Resorbables (3,089,686)
- Laser Hair Removal (1,440,252)
- Non-Invasive Facial Rejuvenation (1,307,300)
- Chemical Peel, CO2 resurfacing, dermabrasion (773,442)
Women had more than 20 million cosmetic procedures; 87.2% of the total. The surgical procedures performed most frequently on women in 2013 were:
- Breast Augmentation
- Breast Lift
Men had more than 3 million cosmetic procedures; 12.8% of the total. The surgical procedures performed the most frequently on men in 2013 were:
- Breast Reduction for Gynecomastia
ISAPS’ latest statistics indicate that cosmetic surgery is on the rise on a global scale. Rankings are based solely on those countries from which a sufficient survey response was received and data were considered to be representative.
PHILADELPHIA, July 28, 2014 /PRNewswire/ — The Intellectual Property and Science Business of Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead’s Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment — $1,000 per pill.
Hepatitis is an inflammation of the liver and there are five main hepatitis viruses, referred to as types A, B, C, D and E — plus types X and G. The five main types are of the greatest concern because of the burden of illness and death they cause and the potential for epidemic outbreaks. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer, killing close to 1.4 million every year according to the World Health Organization (WHO).
In late 2013, Gilead dramatically changed the hepatitis C treatment landscape with the launch of Sovaldi, an effective cure for many when used in combination with ribavirin. However, the high cost of the treatment keeps it out of reach for the majority of the estimated 130-150 million individuals suffering from the disease.
To raise additional awareness for World Hepatitis Day, Life Sciences Connect analysts complied Sovaldi-Innovative, Cost Effective, Unaffordable, utilizing Cortellis™Competitive Intelligence, the pharmaceutical industry’s leading source for drug pipeline, deals, patents, and company content, to evaluate the current outlook of therapies in the pipeline. The analysis revealed several alternative treatments in various stages of development. This high activity is expected to create competition that will lessen costs of treatment, making it more affordable and accessible to patients.
The following were among the key treatments found in different stages of development:
Drug & Mechanism of Action
Indications Under Development
a nucleoside analog NS5B
Phase II for Hepatitis
orally available combination
Potential launch in 2015
veruprevir (HCV NS3/4A protease
Expected launch Q1 2015
The analysis also includes an infographic illustrating significant shifts in the Hepatitis drug market.
“We conducted this study in recognition of World Hepatitis Day to help raise awareness around this potentially devastating disease and spotlight some drugs in development that may help eradicate it,” said Jon Brett-Harris, managing director of Thomson Reuters IP & Science. “One of the largest barriers in treating hepatitis is accessibility, therefore it is critical to identify the key drugs in development that may help make treatment more attainable.”
Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions
HONG KONG, July 28, 2014 /PRNewswire/ — Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that its new PicoWay® device has received CE Mark indication to treat tattoos of all types and colors and pigmented lesions on any skin type. PicoWay is a new and innovative dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes Syneron’s proprietary PicoWay technology to deliver energy to the skin using pulses which are trillionths of a second, known as picosecond pulses. Syneron will begin a staged launch of the PicoWay device in the international market during the third quarter of 2014 and anticipates that it will receive U.S. Food and Drug Administration (FDA) clearance for PicoWay by the end of 2014.
PicoWay’s high peak power and ultra-short pulse duration enable a unique mode of action which creates the strongest photo-mechanical impact to break up the tattoo ink or the pigmentation. This revolutionary PicoWay technology is integrated into a proven, reliable Candela® platform which ensures superior performance and low cost of ownership.
“Our investment in PicoWay’s research and development demonstrate Syneron’s commitment to develop technology that enables physicians to provide best-in-practice treatments for their patients,” stated Amit Meridor, CEO of Syneron. “Since PicoWay has the shortest picosecond pulse duration and the highest peak power of any device on the market, we believe that fewer treatments will be needed and that the percentage clearance will be higher. We are pleased that Dr. Chan will present his positive results with PicoWay at IMCAS Asia, particularly because it will be a significant market for PicoWay due to the special value placed on clear skin in Asia.”
Dr. Henry Chan, specialist in dermatology in Hong Kong, will present the interim results of a multi-center study focused on treating pigmented lesions with PicoWay at the IMCAS Asia Conference slated for August 1-3, 2014 in Hong Kong. His presentation is entitled “The Use of Picosecond Lasers on Asians”.
Dr. Chan says “PicoWay’s unique mode of picosecond action enables full flexibility to adjust the wavelength, fluence, spot size and rep rate, providing customizable treatments which ensure outstanding clinical results. The novel PicoWay technology enables our clinic to offer a new and exciting solution to remove pigmented lesions. The treatments have proven to be effective, safe and comfortable with a high satisfaction rate among our patients.”
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, treatment results, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions, market acceptance of new products, and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Company’s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.’s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.’s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Additional information can be found at www.syneron-candela.com
BEIJING, July 28, 2014 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnos…
SANTA CLARA, Calif., July 28, 2014 /PRNewswire/ — ProteinSimple announced today that it has launched a total protein assay for the Simple Western. This new assay allows users to detect all proteins separated in the assay simultaneously. For the first time, Simple Western users can analyze proteins without the need for an antibody.
The Simple Western has changed protein analysis as we know it today. First, the Simple Western eliminated the hassles of Western blot protocols – no messy gels, no transfer tanks, no blots, no imaging and no manual analysis. Simply load your samples, push a button, walk away and come back to fully analyzed, highly consistent data.
Now, with the Total Protein Master Kit, the benefits of the Simple Western are available to researchers who are currently forced to run a gel and deal with tedious staining protocols just to visualize and quantitate an overexpressed protein or evaluate the amount of a protein in a complex cell lysate. When using the Simple Western platform, these researchers will never have to run a gel again or do that manual analysis.
The Simple Western platform consists of Wes, Sally Sue, and Peggy Sue. These systems can analyze proteins up to 440 kDa in size, either with an antibody-based assay using the standard kits available, or without an antibody using the Total Protein Master Kit.
“For years, researchers have been forced to run gels for either Western blot analysis or total protein detection,” commented John Proctor, Director of Marketing at ProteinSimple. “With this new total protein kit, researchers will never need to run a protein gel again.”
Meet the entire Simple Western family at www.proteinsimple.com.